Post by
longterm56 on Oct 21, 2021 9:31pm
Another disappointing NASH Trial
https://finance.yahoo.com/news/metacrine-reports-interim-results-met642-200100251.html "... and to halt future development of the FXR program in NASH. " Stock down 50% after hours. -LT
Comment by
Wino115 on Oct 22, 2021 8:50am
I've lost track how many FXR agonists have failed. This is just announcing late what was likely inevitable. Intercepts been the biggest bust in the FXR space.